GLP-1s could cause beer sales to take a hit, report says
Half-pints and alcohol-free lagers as the hedge against Ozempic. That's the practical pivot Heineken is apparently recommending, and it makes sense for a company watching its core market shrink one prescription at a time. People on GLP-1s eat and drink less, and beer is a calorie-heavy indulgence that tends to fall by the wayside when appetite vanishes.
What interests me is that the response is about portioning and formulation rather than fighting the trend. No ad campaign trying to convince people that beer is fine in moderation. Just smaller glasses and weaker pours. That's a quiet admission that the industry sees this as a durable shift, not a fad.
I'd want to know how far this extends beyond beer. Wine, spirits, sugary cocktails, even snack foods at bars. If appetite suppression becomes widespread, the whole hospitality sector may need similar adjustments. Heineken's move is sensible, though I wonder if half-pints will feel like a gimmick or an honest accommodation. Either way, it's a reminder that consumer habits can change from the pharmacy counter as much as from the marketing department.